SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From Institute of Microbial Technology (IMTECH) For Clinical Development Of A Novel Clot Busting Therapeutic Protein